Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 215Uterine Cervical Neoplasms 144Endometrial Neoplasms 111Fallopian Tube Neoplasms 78Breast Neoplasms 59Carcinoma, Non-Small-Cell Lung 43Colorectal Neoplasms 40Stomach Neoplasms 35Melanoma 31Carcinoma, Renal Cell 29Prostatic Neoplasms 28Neoplasms 28Carcinoma, Ovarian Epithelial 28Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Esophageal Neoplasms 25Neoplasm Metastasis 24Lung Neoplasms 23Urinary Bladder Neoplasms 22Head and Neck Neoplasms 21Colonic Neoplasms 20Vulvar Neoplasms 19Squamous Cell Carcinoma of Head and Neck 19Carcinoma, Transitional Cell 14Carcinoma, Hepatocellular 14Uterine Neoplasms 13Small Cell Lung Carcinoma 13Sarcoma 13Rectal Neoplasms 12Peritoneal Neoplasms 12

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Fallopian Tube Mucinous Adenocarcinoma × Gynecologic × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡